Gilead Sciences (GILD) leaps on Q1 results, sales

Gilead Sciences (NASDAQ: GILD) surged 2.9% to $75.00 after the company reported better-than-expected first-quarter results and announced strong sales of its hepatitis C drug. Share volume was 15.9 million, catching up to its all-day average